Transcriptomic analysis of EBV LMP1 TES domain(s) single or double mutant and CD40L treatment in EBV-negative BL41 Burkitt-Lymphoma Cells
RNA-seq was used to characterize the LMP1 TES domain-mediated regulation of B-cell genome wide target genes. We created an inducible stable  EBV-negative BL41 Burkitt Lymphoma cell line expressing LMP1 wildtype, TES1 functional only, TES2 functional only and TES1/2 non-functional. wildtype EBV-negative BL41 (no LMP1 transgene) cells were also subjected to CD40L (recombinant CD40 ligand) to study the B-cell target gene regulation in comparison to LMP1 wildtype-mediated. Overall design: Comparative gene expression profiling analysis of RNA-seq data in EBV-negative BL41 Burkitt Lymphoma Cells upon expression of LMP1 wildtype, TES1 only, TES2 only and loss of function of both TES domains. Uninduced cell line (with the LMP1 wildtype transgene) were used as control. Cell untreated with CD40L were used a control for experimental samples (treated with CD40L)